

A1 RECEPTOR" to -- THERAPEUTIC APPLICATIONS FOR CCR5 CHEMOKINE
RECEPTORS

At page 1, please delete at the top of the page "VANMA51.001".

At page 1, please delete the text from "BACKGROUND" to "filed March 3, 1997" and
insert therefore the following paragraph:

--RELATED APPLICATIONS

A2 This application claims priority under 35 U.S.C. § 120 to U.S. Patent Application Serial
No. 09/626,939, filed July 27, 2000, which claims priority under 35 U.S.C. § 120 to U.S. Patent
Application Serial No. 08/833,752, filed April 9, 1997, which claims priority under 35 U.S.C.
§ 119(a)-(d) to EP 96870021.1, filed March 1, 1996, and EP 96870102.9, filed August 6, 1996.--

A marked-up version of page 1 of the specification is attached herewith showing where
changes have been made.

In the Claims

Rule 126 Please **cancel** claims ²⁷1-~~38~~.

Please **add** claims ¹⁻¹³~~39-51~~. 28-40

- A3* ~~28-39~~ 1. A method for decreasing the infectivity of a cell expressing a CCR5 chemokine receptor
by an HIV virus, said method comprising delivering to said cell a CCR5 chemokine
receptor modulator.
- ~~29-40~~ 2. The method according to claim ~~39~~, wherein said CCR chemokine receptor modulator
comprises an antagonist of said CCR5 chemokine.
- ~~30-41~~ 3. The method according to claim ~~39~~, wherein said modulator is a polypeptide.